Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval 04/01/2024 majac COPD Chronic Obstructive Pulmonary Disease COPD Concept. IvelinRadkov. Sanofi (NASDAQ:SNY) and Regeneron Pharmaeuticals (NASDAQ:REGN) Dupixent … Share on FacebookTweetFollow usSave